<DOC>
	<DOCNO>NCT01051609</DOCNO>
	<brief_summary>The purpose study compare pre post Aromatase Inhibitor ( AI ) treatment serological marker inflammation assess correlation AI-MS .</brief_summary>
	<brief_title>Aromatase Inhibitor-Associated Musculoskeletal Symptoms Non-Metastatic , Post Menopausal Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Women 18 year older nonmetastatic hormone receptor ( ER and/or PR ) positive breast cancer eligible plan start treatment AI within one month sign consent . Postmenopausal , define least one following : ) amenorrhea least 12 month b ) prior bilateral oophorectomy least 2 year prior trial registration . History autoimmune connective tissue disease , rheumatoid arthritis , lupus , autoimmune condition affect joint . Treatment steroid ( condition , except chemotherapy premedication ) within 30 day trial registration . Prior treatment AI ( patient previously currently tamoxifen eligible long patient tamoxifen 2 week prior baseline blood draw ) Active ongoing infection Known metastatic disease Known history HIV hepatitis infection Ongoing radiation therapy ( radiation must complete 2 week prior start treatment AI ) Noninvasive ( DCIS , LCIS ) cancer ( diagnosis invasive cancer ) Pregnant lactate Unable speak , read , write English</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Post Menopausal</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>